nach oben

Heart and Vessels

Erschienen in:

04.05.2020 | Original Article

Relationship between adenosine A2a receptor polymorphism rs5751876 and fractional flow reserve during percutaneous coronary intervention

verfasst von: Matteo Nardin, Monica Verdoia, Federica Negro, Harry Suryapranata, Elvin Khedi, Giuseppe De Luca

Erschienen in: Heart and Vessels | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Fractional flow reserve (FFR) assessed during adenosine-induced maximal hyperemia has emerged as a useful tool for the guidance of percutaneous coronary interventions (PCI). However, interindividual variability in the response to adenosine has been claimed as a major limitation to the use of adenosine for the measurement of FFR, carrying the risk of underestimating the severity of coronary stenoses, with potential negative prognostic consequences. Genetic variants of the adenosine receptor A2a (ADORA2A gene), located in the coronary circulation, have been involved in the modulation of the hyperemic response to adenosine. However, no study has so far evaluated the impact of the single nucleotide polymorphism rs5751876 of ADORA2A on the measurement of FFR in patients undergoing percutaneous coronary intervention that was, therefore, the aim of our study. We included patients undergoing coronary angiography and FFR assessment for intermediate (40–70%) coronary lesions. FFR measurement was performed by pressure-recording guidewire (Prime Wire, Volcano), after induction of hyperemia with intracoronary boli of adenosine (from 60 to 1440 μg, with dose doubling at each step). Restriction fragment length polymorphism (RFLP) analysis was performed to assess the presence of rs5751876 C>T polymorphism of ADORA2a receptor. We included 204 patients undergoing FFR measurement of 231 coronary lesions. A total of 134 patients carried the polymorphism (T allele), of whom 41 (30.6%) in homozygosis (T/T).Main clinical and angiographic features did not differ according to ADORA2A genotype. The rs5751876 C>T polymorphism did not affect mean FFR values (p = 0.91), the percentage of positive FFR (p = 0.54) and the duration of maximal hyperemia. However, the time to recovery to baseline FFR values was more prolonged among the T-allele carriers as compared to wild-type patients (p = 0.04). Based on these results, in patients with intermediate coronary stenoses undergoing FFR assessment with adenosine, the polymorphism rs5751876 of ADORA2A does not affect the peak hyperemic response to adenosine and the results of FFR. However, a more prolonged effect of adenosine was observed in T-carriers.

WHO (2019). https://apps.who.int/gho/data/node.main. Accessed 25 Nov 2019

Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GBJ, Weintraub WS (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503–1516PubMedCrossRef

Maron DJ, Hochman JS, O’Brien SM, Reynolds HR, Boden WE, Stone GW, Bangalore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB, Williams DO, Harrington RA, Rosenberg Y (2018) International study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA) trial: rationale and design. Am Heart J 201:124–135PubMedCrossRef

Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, Wijns W, Glineur D, Aboyans V, Achenbach S, Agewall S, Andreotti F, Barbato E, Baumbach A, Brophy J, Bueno H, Calvert PA, Capodanno D, Davierwala PM, Delgado V, Dudek D, Freemantle N, Funck-Brentano C, Gaemperli O, Gielen S, Gilard M, Gorenek B, Haasenritter J, Haude M, Ibanez B, Iung B, Jeppsson A, Katritsis D, Knuuti J, Kolh P, Leite-Moreira A, Lund LH, Maisano F, Mehilli J, Metzler B, Montalescot G, Pagano D, Petronio AS, Piepoli MF, Popescu BA, Sádaba R, Shlyakhto E, Silber S, Simpson IA, Sparv D, Tavilla G, Thiele H, Tousek P, Van Belle E, Vranckx P, Witkowski A, Zamorano JL, Roffi M, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J-P, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Sousa-Uva M, Simpson IA, Zamorano JL, Pagano D, Freemantle N, Sousa-Uva M, Chettibi M, Sisakian H, Metzler B, İbrahimov F, Stelmashok VI, Postadzhiyan A, Skoric B, Eftychiou C, Kala P, Terkelsen CJ, Magdy A, Eha J, Niemelä M, Kedev S, Motreff P, Aladashvili A, Mehilli J, Kanakakis I-G, Becker D, Gudnason T, Peace A, Romeo F, Bajraktari G, Kerimkulova A, Rudzītis A, Ghazzal Z, Kibarskis A, Pereira B, Xuereb RG, Hofma SH, Steigen TK, Witkowski A, de Oliveira EI, Mot S, Duplyakov D, Zavatta M, Beleslin B, Kovar F, Bunc M, Ojeda S, Witt N, Jeger R, Addad F, Akdemir R, Parkhomenko A, Henderson R (2018) 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 40:87–165CrossRef

Pijls NH, van Son JA, Kirkeeide RL, De Bruyne B, Gould KL (1993) Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation 87:1354–1367PubMedCrossRef

Pijls NHJ, van Schaardenburgh P, Manoharan G, Boersma E, Bech J-W, van’t Veer M, Bär F, Hoorntje J, Koolen J, Wijns W, de Bruyne B (2007) Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER study. J Am Coll Cardiol 49:2105–2111PubMedCrossRef

Tonino PAL, De Bruyne B, Pijls NHJ, Siebert U, Ikeno F, van’t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360:213–224PubMedCrossRef

Röther J, Achenbach S, Tröbs M, Blachutzik F, Nef H, Marwan M, Schlundt C (2016) Comparison of standard- and high-dose intracoronary adenosine for the measurement of coronary fractional flow reserve (FFR). Clin Res Cardiol 105:1003–1010PubMedCrossRef

De Bruyne B, Pijls NHJ, Barbato E, Bartunek J, Bech J-W, Wijns W, Heyndrickx GR (2003) Intracoronary and intravenous adenosine 5′-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation 107:1877–1883PubMedCrossRef

10.

Chen J-F, Eltzschig HK, Fredholm BB (2013) Adenosine receptors as drug targets—what are the challenges? Nat Rev Drug Discov 12:265–286PubMedPubMedCentralCrossRef

11.

Shryock JC, Snowdy S, Baraldi PG, Cacciari B, Spalluto G, Monopoli A, Ongini E, Baker SP, Belardinelli L (1998) A2A-adenosine receptor reserve for coronary vasodilation. Circulation 98:711–718PubMedCrossRef

12.

Gariboldi V, Vairo D, Guieu R, Marlingue M, Ravis E, Lagier D, Mari A, Thery E, Collart F, Gaudry M, Bonello L, Paganelli F, Condo J, Kipson N, Fenouillet E, Ruf J, Mottola G (2017) Expressions of adenosine A2A receptors in coronary arteries and peripheral blood mononuclear cells are correlated in coronary artery disease patients. Int J Cardiol 230:427–431PubMedCrossRef

13.

Fenouillet E, Mottola G, Kipson N, Paganelli F, Guieu R, Ruf J (2019) Adenosine receptor profiling reveals an association between the presence of spare receptors and cardiovascular disorders. Int J Mol Sci 20:E5964PubMedCrossRef

14.

Hohoff C, McDonald JM, Baune BT, Cook EH, Deckert J, de Wit H (2005) Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants. Am J Med Genet B Neuropsychiatr Genet 139B:42–44PubMedCrossRef

15.

Chen X, Xue A, Chen W, Ding Y, Yan D, Peng J, Zeng C, Qu J, Zhou X (2011) Assessment of exonic single nucleotide polymorphisms in the adenosine A2A receptor gene to high myopia susceptibility in Chinese subjects. Mol Vis 17:486–491PubMedPubMedCentral

16.

De Luca G, Secco GG, Santagostino M, Venegoni L, Iorio S, Cassetti E, Verdoia M, Coppo L, Di Mario C, Bellomo G, Marino P (2012) Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 22:426–433PubMedCrossRef

17.

De Luca G, Venegoni L, Iorio S, Giuliani L, Marino P (2011) Effects of increasing doses of intracoronary adenosine on the assessment of fractional flow reserve. JACC Cardiovasc Interv 4:1079–1084PubMedCrossRef

18.

Verdoia M, Erbetta R, Sagazio E, Barbieri L, Negro F, Suryapranata H, Kedhi E, De Luca G, Novara Atherosclerosis Study Group (NAS) (2018) Impact of increasing dose of intracoronary adenosine on peak hyperemia duration during fractional flow reserve assessment. Int J Cardiol 284:16–21PubMedCrossRef

19.

Verdoia M, Barbieri L, Kedhi E, Suryapranata H, De Luca G (2018) Percutaneous versus surgical revascularization for left main or multivessel coronary artery disease: results from a large-scale meta-analysis in the era of drug-eluting stents. Angiology 69:812–824PubMedCrossRef

20.

De Luca G, Smits P, Hofma SH, Di Lorenzo E, Vlachojannis GJ, van’t Hof AWJ, van Boven AJ, Kedhi E, Stone GW, Suryapranata H (2017) Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Int J Cardiol 244:121–127PubMedCrossRef

21.

De Luca G, Dirksen MT, Kelbæk H, Thuesen L, Vink MA, Kaiser C, Chechi T, Spaziani G, Di Lorenzo E, Suryapranata H, Stone GW (2015) Paclitaxel-eluting versus bare metal stents in primary PCI: a pooled patient-level meta-analysis of randomized trials. J Thromb Thrombolysis 39:101–112PubMedCrossRef

22.

Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, Tonino PAL, Engstrøm T, Kääb S, Dambrink J-H, Rioufol G, Toth GG, Piroth Z, Witt N, Fröbert O, Kala P, Linke A, Jagic N, Mates M, Mavromatis K, Samady H, Irimpen A, Oldroyd K, Campo G, Rothenbühler M, Jüni P, De Bruyne B (2018) Five-year Outcomes with PCI guided by fractional flow reserve. N Engl J Med 379:250–259PubMedCrossRef

23.

Johnson NP, Tóth GG, Lai D, Zhu H, Açar G, Agostoni P, Appelman Y, Arslan F, Barbato E, Chen S-L, Di Serafino L, Domínguez-Franco AJ, Dupouy P, Esen AM, Esen ÖB, Hamilos M, Iwasaki K, Jensen LO, Jiménez-Navarro MF, Katritsis DG, Kocaman SA, Koo B-K, López-Palop R, Lorin JD, Miller LH, Muller O, Nam C-W, Oud N, Puymirat E, Rieber J, Rioufol G, Rodés-Cabau J, Sedlis SP, Takeishi Y, Tonino PAL, Van Belle E, Verna E, Werner GS, Fearon WF, Pijls NHJ, De Bruyne B, Gould KL (2014) Prognostic value of fractional flow reserve. J Am Coll Cardiol 64:1641–1654PubMedCrossRef

24.

Davies JE, Sen S, Dehbi H-M, Al-Lamee R, Petraco R, Nijjer SS, Bhindi R, Lehman SJ, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M, Van Belle E, Krackhardt F, Bojara W, Going O, Härle T, Indolfi C, Niccoli G, Ribichini F, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H, Canas Silva P, Baptista SB, Alghamdi A, Hellig F, Koo B-K, Nam C-W, Shin E-S, Doh J-H, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, van Royen N, Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K, Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbanda RK, Patel MR, Serruys P, Escaned J (2017) Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med 376:1824–1834PubMedCrossRef

25.

Götberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, Olsson S-E, Öhagen P, Olsson H, Omerovic E, Calais F, Lindroos P, Maeng M, Tödt T, Venetsanos D, James SK, Kåregren A, Nilsson M, Carlsson J, Hauer D, Jensen J, Karlsson A-C, Panayi G, Erlinge D, Fröbert O (2017) Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med 376:1813–1823PubMedCrossRef

26.

Berger A, Botman K-J, MacCarthy PA, Wijns W, Bartunek J, Heyndrickx GR, Pijls NHJ, De Bruyne B (2005) Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. J Am Coll Cardiol 46:438–442PubMedCrossRef

27.

Courtis J, Rodés-Cabau J, Larose E, Déry J-P, Nguyen CM, Proulx G, Gleeton O, Roy L, Barbeau G, Noël B, DeLarochellière R, Bertrand OF (2008) Comparison of medical treatment and coronary revascularization in patients with moderate coronary lesions and borderline fractional flow reserve measurements. Catheter Cardiovasc Interv 71:541–548PubMedCrossRef

28.

Depta JP, Patel JS, Novak E, Masrani SK, Raymer D, Facey G, Patel Y, Zajarias A, Lasala JM, Singh J, Bach RG, Kurz HI (2014) Outcomes of coronary stenoses deferred revascularization for borderline versus nonborderline fractional flow reserve values. Am J Cardiol 113:1788–1793PubMedCrossRef

29.

Niccoli G, Indolfi C, Davies JE (2017) Evaluation of intermediate coronary stenoses in acute coronary syndromes using pressure guidewire. Open Hear 4:e000431CrossRef

30.

Casella G, Leibig M, Schiele TM, Schrepf R, Seelig V, Stempfle H-U, Erdin P, Rieber J, König A, Siebert U, Klauss V (2004) Are high doses of intracoronary adenosine an alternative to standard intravenous adenosine for the assessment of fractional flow reserve? Am Heart J 148:590–595PubMedCrossRef

31.

Jeremias A, Whitbourn RJ, Filardo SD, Fitzgerald PJ, Cohen DJ, Tuzcu EM, Anderson WD, Abizaid AA, Mintz GS, Yeung AC, Kern MJ, Yock PG (2000) Adequacy of intracoronary versus intravenous adenosine-induced maximal coronary hyperemia for fractional flow reserve measurements. Am Heart J 140:651–657PubMedCrossRef

32.

Leone AM, Porto I, De Caterina AR, Basile E, Aurelio A, Gardi A, Russo D, Laezza D, Niccoli G, Burzotta F, Trani C, Mazzari MA, Mongiardo R, Rebuzzi AG, Crea F (2012) Maximal hyperemia in the assessment of fractional flow reserve: intracoronary adenosine versus intracoronary sodium nitroprusside versus intravenous adenosine: the NASCI (Nitroprussiato versus Adenosina nelle Stenosi Coronariche Intermedie) study. JACC Cardiovasc Interv 5:402–408PubMedCrossRef

33.

Gili S, Barbero U, Errigo D, De Luca G, Biondi-Zoccai G, Leone AM, Iannaccone M, Montefusco A, Omedé P, Moretti C, D’Amico M, Gaita F, D’Ascenzo F (2018) Intracoronary versus intravenous adenosine to assess fractional flow reserve: a systematic review and meta-analysis. J Cardiovasc Med 19:274–283CrossRef

34.

Kern MJ, Deligonul U, Tatineni S, Serota H, Aguirre F, Hilton TC (1991) Intravenous adenosine: continuous infusion and low dose bolus administration for determination of coronary vasodilator reserve in patients with and without coronary artery disease. J Am Coll Cardiol 18:718–729PubMedCrossRef

35.

Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD (1990) Effects of adenosine on human coronary arterial circulation. Circulation 82:1595–1606PubMedCrossRef

36.

Murtagh B, Higano S, Lennon R, Mathew V, Holmes DR, Lerman A (2003) Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment. Am Heart J 146:99–105PubMedCrossRef

37.

Kimchi-Sarfaty C, Oh JM, Kim I-W, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315:525–528PubMedCrossRef

38.

Guieu R, Kipson N, Ruf J, Fournier N, Laine M, Foucher MC, Fromonot J, Mottola G, Bruzzese L, Boussuges A, Fenouillet E, Bonello L, Paganelli F (2015) Low basal expression of A2A adenosine receptors and increase in adenosine plasma concentration are associated with positive exercise stress testing. Int J Cardiol 180:15–17PubMedCrossRef

39.

Beste C, Stock A-K, Ness V, Epplen JT, Arning L (2012) Differential effects of ADORA2A gene variations in pre-attentive visual sensory memory subprocesses. Eur Neuropsychopharmacol 22:555–561PubMedCrossRef

40.

Alsene K, Deckert J, Sand P, de Wit H (2003) Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28:1694–1702PubMedCrossRef

41.

Deckert J, Nöthen MM, Franke P, Delmo C, Fritze J, Knapp M, Maier W, Beckmann H, Propping P (1998) Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Mol Psychiatry 3:81–85PubMedCrossRef

42.

Riksen NP, Franke B, van den Broek P, Smits P, Rongen GA (1976C) The 1976C%3eT polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet Genom 17:551–554CrossRef

43.

Andreassi MG, Laghi Pasini F, Picano E, Capecchi PL, Pompella G, Foffa I, Borghini A, Sicari R (2011) Adenosine A2(A) receptor gene polymorphism (1976C%3eT) affects coronary flow reserve response during vasodilator stress testing in patients with non ischemic-dilated cardiomyopathy. Pharmacogenet Genom 21:469–475CrossRef

44.

Saadjian AY, Gerolami V, Giorgi R, Mercier L, Berge-Lefranc J-L, Paganelli F, Ibrahim Z, By Y, Guéant JL, Lévy S, Guieu RP (2009) Head-up tilt induced syncope and adenosine A2A receptor gene polymorphism. Eur Heart J 30:1510–1515PubMedCrossRef

45.

Nardin M, Verdoia M, Pergolini P, Rolla R, Barbieri L, Marino P, Bellomo G, Kedhi E, Suryapranata H, Carriero A, De Luca G (2018) Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. Pharmacol Res 129:27–33PubMedCrossRef

46.

Rétey JV, Adam M, Khatami R, Luhmann UFO, Jung HH, Berger W, Landolt H-P (2007) A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther 81:692–698PubMedCrossRef

47.

Yamada K, Kobayashi M, Kanda T (2014) Involvement of adenosine A2A receptors in depression and anxiety. Int Rev Neurobiol 119:373–393PubMedCrossRef

48.

Childs E, Hohoff C, Deckert J, Xu K, Badner J, de Wit H (2008) Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 33:2791–2800PubMedCrossRef

Titel: Relationship between adenosine A2a receptor polymorphism rs5751876 and fractional flow reserve during percutaneous coronary intervention
verfasst von: Matteo Nardin
Monica Verdoia
Federica Negro
Harry Suryapranata
Elvin Khedi
Giuseppe De Luca
Publikationsdatum: 04.05.2020
Verlag: Springer Japan
Erschienen in: Heart and Vessels / Ausgabe 10/2020
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-020-01609-w

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Relationship between adenosine A2a receptor polymorphism rs5751876 and fractional flow reserve during percutaneous coronary intervention

Abstract

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

Oscillating shear stress mediates mesenchymal transdifferentiation of EPCs by the Kir2.1 channel

On-site assessment of computed tomography-derived fractional flow reserve in comparison with myocardial perfusion imaging and invasive fractional flow reserve

Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia

Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes

Chemoradiation therapy for non-small cell lung cancer exacerbates thoracic aortic calcification determined by computed tomography

Aortic valve replacement with or without concomitant coronary artery bypass grafting in very elderly patients aged 85 years and older

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie